BSEN760

BSEN760 is a novel, potent, and selective orally active investigational small molecule drug developed by Bsense Bio Therapeutics for the treatment of chronic pain and sensory hyperexcitability disorders. It acts as a dual modulator by simultaneously activating Kv7.2/3 (KCNQ2/KCNQ3) potassium channels and inhibiting the TRPV1 receptor. This dual mechanism dampens sensory neuron hyperexcitability, providing synergistic activity for pain alleviation with potentially fewer side effects compared to current standard-of-care treatments. The compound demonstrates high potency in preclinical models of chronic pain at low exposures, suggesting a wide therapeutic window and improved safety profile over existing therapies[1][2][3][4][5][6].